EP3228313 - DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE [Right-click to bookmark this link] | |||
Former [2017/41] | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE | ||
[2019/15] | Status | No opposition filed within time limit Status updated on 17.07.2020 Database last updated on 22.05.2024 | |
Former | The patent has been granted Status updated on 09.08.2019 | ||
Former | Grant of patent is intended Status updated on 20.03.2019 | ||
Former | Examination is in progress Status updated on 12.10.2018 | ||
Former | Request for examination was made Status updated on 13.04.2018 | ||
Former | The application has been published Status updated on 08.09.2017 | Most recent event Tooltip | 15.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 17.08.2022 [2022/33] | Applicant(s) | For all designated states Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080 / US | [2017/41] | Inventor(s) | 01 /
Snodgrass, Ralph H. 20781 Via Corta San Jose, CA California 95120 / US | 02 /
Cato, Allen E. Cato Research, 4364 S. Alston Avenue Durham, NC North Carolina 27713 / US | 03 /
Hicklin, Jack S. Cato Research, 6480 Weathers Place, Suite 104 San Diego, CA California 92121 / US | [2017/41] | Representative(s) | Jacobi, Markus Alexander Patentanwälte Isenbruck Bösl Hörschler PartG mbB Eastsite One Seckenheimer Landstraße 4 68163 Mannheim / DE | [2019/37] |
Former [2017/41] | Jacobi, Markus Alexander Isenbruck Bösl Hörschler LLP Patentanwälte Eastsite One Seckenheimer Landstraße 4 68163 Mannheim / DE | Application number, filing date | 17170079.2 | 22.01.2014 | [2017/41] | Priority number, date | US201361849191P | 22.01.2013 Original published format: US 201361849191 P | [2017/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3228313 | Date: | 11.10.2017 | Language: | EN | [2017/41] | Type: | B1 Patent specification | No.: | EP3228313 | Date: | 11.09.2019 | Language: | EN | [2019/37] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 07.09.2017 | Classification | IPC: | A61K31/198, A61P25/28, A61P25/24, A61P25/14, A61P25/04 | [2017/41] | CPC: |
A61K31/198 (EP,IL,KR,US);
A61K9/0053 (IL,US);
A61P25/04 (EP,IL);
A61P25/24 (KR);
A61K2300/00 (IL);
Y02A50/30 (EP)
| C-Set: |
A61K31/198, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/20] |
Former [2017/41] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | DOSIERUNGSFORMEN UND THERAPEUTISCHE VERWENDUNGEN VON L-4-CHLORKYNURENIN | [2017/41] | English: | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | [2019/15] | French: | FORMES POSOLOGIQUES ET UTILISATIONS THÉRAPEUTIQUES DE LA L-4-CHLOROCYNURÉNINE | [2017/41] |
Former [2017/41] | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE | Examination procedure | 09.05.2017 | Date on which the examining division has become responsible | 14.02.2018 | Amendment by applicant (claims and/or description) | 10.04.2018 | Examination requested [2018/20] | 10.10.2018 | Despatch of a communication from the examining division (Time limit: M04) | 18.02.2019 | Reply to a communication from the examining division | 21.03.2019 | Communication of intention to grant the patent | 31.07.2019 | Fee for grant paid | 31.07.2019 | Fee for publishing/printing paid | 31.07.2019 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP14743570.5 / EP2948140 | Divisional application(s) | EP19196366.9 / EP3598971 | EP24164414.5 | Opposition(s) | 15.06.2020 | No opposition filed within time limit [2020/34] | Fees paid | Renewal fee | 09.05.2017 | Renewal fee patent year 03 | 09.05.2017 | Renewal fee patent year 04 | 29.01.2018 | Renewal fee patent year 05 | 28.01.2019 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 22.01.2014 | AL | 11.09.2019 | CZ | 11.09.2019 | EE | 11.09.2019 | FI | 11.09.2019 | LT | 11.09.2019 | LV | 11.09.2019 | MC | 11.09.2019 | MK | 11.09.2019 | MT | 11.09.2019 | NL | 11.09.2019 | RO | 11.09.2019 | SK | 11.09.2019 | SM | 11.09.2019 | NO | 11.12.2019 | GR | 12.12.2019 | IS | 12.01.2020 | LU | 22.01.2020 | [2022/33] |
Former [2022/29] | HU | 22.01.2014 | |
AL | 11.09.2019 | ||
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
MC | 11.09.2019 | ||
MT | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
SM | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 12.01.2020 | ||
LU | 22.01.2020 | ||
Former [2020/46] | AL | 11.09.2019 | |
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
MC | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
SM | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 12.01.2020 | ||
LU | 22.01.2020 | ||
Former [2020/39] | AL | 11.09.2019 | |
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
MC | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
SM | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 12.01.2020 | ||
Former [2020/36] | AL | 11.09.2019 | |
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
SM | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 12.01.2020 | ||
Former [2020/27] | AL | 11.09.2019 | |
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
SM | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 24.02.2020 | ||
Former [2020/26] | AL | 11.09.2019 | |
CZ | 11.09.2019 | ||
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
SK | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
IS | 24.02.2020 | ||
Former [2020/23] | AL | 11.09.2019 | |
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
RO | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
Former [2020/22] | AL | 11.09.2019 | |
EE | 11.09.2019 | ||
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
Former [2020/20] | AL | 11.09.2019 | |
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NL | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
Former [2020/15] | AL | 11.09.2019 | |
FI | 11.09.2019 | ||
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
Former [2020/12] | FI | 11.09.2019 | |
LT | 11.09.2019 | ||
LV | 11.09.2019 | ||
NO | 11.12.2019 | ||
GR | 12.12.2019 | ||
Former [2020/09] | FI | 11.09.2019 | |
LT | 11.09.2019 | ||
NO | 11.12.2019 | ||
Former [2020/08] | LT | 11.09.2019 | |
NO | 11.12.2019 | Documents cited: | Search | [A]US2011306674 (SCHIENE KLAUS [DE], et al) [A] 1-15 * the whole document * * paragraphs [0029] , [0075]; claims 1,6 *; | [A] - HUI-QIU WU ET AL, "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", EUROPEAN JOURNAL OF PHARMACOLOGY, NL, (20000301), vol. 390, no. 3, doi:10.1016/S0014-2999(00)00024-8, ISSN 0014-2999, pages 267 - 274, XP055269951 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0014-2999(00)00024-8 | [A] - SONG-CHU LEE ET AL, "Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo", NEUROSCIENCE LETTERS, IE, (20010501), vol. 304, no. 3, doi:10.1016/S0304-3940(01)01791-8, ISSN 0304-3940, pages 185 - 188, XP055283122 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0304-3940(01)01791-8 | [A] - PAOLO GUIDETTI ET AL, "In Situ Produced 7-Chlorokynurenate Provides Protection against Quinolinate- and Malonate-Induced Neurotoxicity in the Rat Striatum", EXPERIMENTAL NEUROLOGY, US, (20000501), vol. 163, no. 1, doi:10.1006/exnr.1999.7284, ISSN 0014-4886, pages 123 - 130, XP055283120 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1006/exnr.1999.7284 | [A] - LINDERHOLM ET AL, "Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, (20071122), vol. 53, no. 8, doi:10.1016/J.NEUROPHARM.2007.09.003, ISSN 0028-3908, pages 918 - 924, XP022358184 [A] 1-15 * the whole document * * page 919, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1016/j.neuropharm.2007.09.003 | [A] - HUI-QIU WU ET AL, "Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo", EUROPEAN JOURNAL OF PHARMACOLOGY, NL, (19970101), vol. 319, no. 1, doi:10.1016/S0014-2999(96)00829-1, ISSN 0014-2999, pages 13 - 20, XP055283118 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0014-2999(96)00829-1 | [T] - P. ZANOS ET AL, "The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20150811), vol. 355, no. 1, doi:10.1124/jpet.115.225664, pages 76 - 85, XP055283128 [T] 1-12 * the whole document * DOI: http://dx.doi.org/10.1124/jpet.115.225664 | by applicant | US5547991 | - SALITURO ET AL., "Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor", J. MED. CHEM., (1994), vol. 37, page 334,336 | - CALABRESE ET AL., "Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment", PLOS ONE, (2012), vol. 7, no. 5, page E37916 | - CARTER AJ, "Glycine antagonist: Regulation of the NMDA receptor channel complex by the strychnine-insensitive glycine site", DRUGS FUTURE, (1992), vol. 17, pages 595 - 613 | - CATARZI ET AL., "Competitive Gly/NMDA receptor antagonists", CURR. TOP. MED. CHEM., (2006), vol. 6, no. 8, pages 809 - 821 | - HOKARI M; WU H-Q; SCHWARCZ R; SMITH QR, "Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid", NEUROREPORT, (1996), vol. 8, no. 1, pages 15 - 18 | - KEMP JA ET AL., "7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex", PROC NATL ACADS SCI U.S.A., (1988), vol. 85, no. 17, pages 6547 - 6550 | - LEE S-C; SCHWARCZ R, "Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo", NEUROSCIENCE LETT, (2001), vol. 304, no. 3, pages 185 - 188 | - LEESON PD; IVERSEN LL, "The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential", J MED CHEM, (1994), vol. 37, no. 24, pages 4053 - 4067 | - LINDERHOLM ET AL., "Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis", NEUROPHARMACOLOGY, (2007), vol. 53, no. 8, pages 918 - 924 | - PARSONS CG ET AL., "Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization", J PHARMACOL EXP THER, (1997), vol. 283, no. 3, pages 1264 - 1275 | - RAO TS; GRAY NM; DAPPEN MS; CLER JA; MICK SJ; EMMETT MR ET AL., "Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization", NEUROPHARMACOL, (1993), vol. 32, no. 2, pages 139 - 147 | - RUNDFELDT C; WLAZ P; LOSCHER W, "Anticonvulsant activity of antagonists and partial agonists for the NMDA receptor-associated glycine site in the kindling model of epilepsy", BRAIN RES, (1994), vol. 653, no. 1-2, pages 125 - 130 | - WU HQ; LEE SC; SCHARFMAN HE; SCHWARCZ R, "L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat", EXP NEUROL, (2002), vol. 177, no. 1, pages 222 - 232 | - WU H-Q; LEE S-C; SCHWARCZ R, "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", EUR J PHARM, (2000), vol. 390, pages 267 - 274 |